ArticleJournal of nanobiotechnology2026
Rationally engineered cationic ferritin nanoparticles overcome pre-existing immunity to adenoviral vectors.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Viral vectors and protein nanoparticles represent important platforms in vaccine delivery, yet their potential synergy to overcome fundamental biological barriers remains largely unexplored. To address the challenge of pre-existing immunity against viral vectors, we rationally engineered a cationic human ferritin nanoparticle, termed (+)hF, designed to electrostatically assembles with adenovirus serotype 5 (Ad5) into a supramolecular complex. This construct was generated via structure-guided point mutations that introduced positive surface charges while retaining the innate self-assembly capability of the ferritin nanocage. The resulting (+)hF formed nanocomplexes with Ad5, which enhanced transgene expressions both in vitro and in vivo and effectively reduced sensitively to anti-Ad5 neutralization. In murine models with pre-existing immunity, intranasal immunization with (+)hF-complexed Ad5-based vaccines (encoding antigens for SARS-CoV-2 or Hendra virus) elicited significantly higher antigen-specific IgG and neutralizing antibody titers. A key advantage of (+)hF is its endogenous origin, which ensures high biocompatibility by preventing the induction of anti-carrier antibodies and any associated immune burden. This study presents a new paradigm that engineers programmable biointerfaces to synergize viral vectors with protein nanocages, offering a general strategy to circumvent critical biological barriers for enhanced vaccine and gene delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.